The study on dendritic cell vaccine against glioblastoma, the most common and aggressive type of malignant brain tumor, was awarded by the USA Brain Tumor Society, during the Congress of Neurological Surgeons that took place in October in Texas, United States.

The surgeon Prof. Guilherme Lepski, Associate Professor at the Faculdade de Medicina da Universidade de São Paulo (FMUSP) Department of Neurology, is one of the scientists who participated in the development of the vaccine.

According to the professor, "the recognition of such a prestigious society reinforces our commitment to help patients with glioblastoma and support their families."

The vaccine to fight glioblastoma was the result of a partnership between the Department of Neurology at FMUSP and the Department of Immunology at the Institute of Biomedical Sciences at USP.

Developed from international studies related to immunotherapy, the vaccine uses dendritic cells to activate a more effective response from the patient's own defense system.

The positive results of the immunizing agent in combating glioblastoma may, in the near future, complement procedures such as surgery, chemotherapy and radiotherapy, usually used in the treatment of cancer.